Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
???displayArticle.abstract???
The alpha7 subtype of the nicotinic acetylcholine receptor (nAChR) is the target of studies aimed at identifying features that will lead to the development of selective therapeutics. Five arylidine anabaseines, three with pyridine rings and two with the pyrrole rings, were synthesized in 35-65% yield via aldol condensation. The compounds are homologs of benzylidine anabaseine and were chosen for synthesis because they provide either a hydrogen bond acceptor (pyridines) or hydrogen bond donor (pyrroles) that may interact with the receptor within the benzylidine selectivity motif. Initial analysis of the new compounds at 100 microM concentration reveal that the two pyrrole anabaseines are good partial agonists of the alpha7 nAChR, having 40% of the efficacy of ACh, efficacy comparable to 4OH-GTS-21, and dramatically enhanced efficacy relative to the 2- and 4-pyridinyl compounds. The pyrrole compounds were confirmed to be alpha7 selective, displaying preference for this receptor over muscle and heteromeric neuronal receptor subtypes.
Carson,
Alpha7 nicotinic acetylcholine receptor gene and reduced risk of Alzheimer's disease.
2008, Pubmed
Carson,
Alpha7 nicotinic acetylcholine receptor gene and reduced risk of Alzheimer's disease.
2008,
Pubmed
Damaj,
Characterization of spontaneous and precipitated nicotine withdrawal in the mouse.
2003,
Pubmed
Damaj,
Pharmacological characterization of nicotine-induced seizures in mice.
1999,
Pubmed
Dani,
Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system.
2007,
Pubmed
de Jonge,
The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation.
2007,
Pubmed
Flores,
A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment.
1992,
Pubmed
Franceschini,
Altered baroreflex responses in alpha7 deficient mice.
2000,
Pubmed
Horenstein,
Multiple pharmacophores for the selective activation of nicotinic alpha7-type acetylcholine receptors.
2008,
Pubmed
,
Xenbase
Katritzky,
Novel syntheses of enantiopure hexahydroimidazo[1,5-b]isoquinolines and tetrahydroimidazo[1,5-b]isoquinolin-1(5H)-ones via iminium cation cyclizations.
2002,
Pubmed
Kem,
Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration.
2004,
Pubmed
,
Xenbase
Leonik,
Quinuclidines as selective agonists for alpha-7 nicotinic acetylcholine receptors.
2007,
Pubmed
,
Xenbase
Meyer,
3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner.
1997,
Pubmed
,
Xenbase
Papke,
Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis.
2002,
Pubmed
,
Xenbase
Papke,
Effects at a distance in alpha 7 nAChR selective agonists: benzylidene substitutions that regulate potency and efficacy.
2004,
Pubmed
,
Xenbase
Romanelli,
Central nicotinic receptors: structure, function, ligands, and therapeutic potential.
2007,
Pubmed
Sharma,
Nicotinic receptor signaling in nonexcitable cells.
2002,
Pubmed
Waldo,
Familial transmission of risk factors in the first-degree relatives of schizophrenic people.
2000,
Pubmed
Whiting,
Characterization of bovine and human neuronal nicotinic acetylcholine receptors using monoclonal antibodies.
1988,
Pubmed
